Keith Regnante
2021
In 2021, Keith Regnante earned a total compensation of $3M as Chief Financial Officer at Keros Therapeutics, a 29% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $200,900 |
|---|---|
| Option Awards | $2,444,315 |
| Salary | $401,800 |
| Other | $540 |
| Total | $3,047,555 |
Regnante received $2.4M in option awards, accounting for 80% of the total pay in 2021.
Regnante also received $200.9K in non-equity incentive plan, $401.8K in salary and $540 in other compensation.
Rankings
In 2021, Keith Regnante's compensation ranked 4,369th out of 12,415 executives tracked by ExecPay. In other words, Regnante earned more than 64.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,369 out of 12,415 | 65th |
Division Manufacturing | 1,801 out of 5,508 | 67th |
Major group Chemicals And Allied Products | 757 out of 2,378 | 68th |
Industry group Drugs | 675 out of 2,099 | 68th |
Industry Pharmaceutical Preparations | 480 out of 1,549 | 69th |
Source: SEC filing on April 18, 2022.
Regnante's colleagues
We found two more compensation records of executives who worked with Keith Regnante at Keros Therapeutics in 2021.